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RESUMO.- [Efeitos do uso tópico da Ciclosporina A (CsA)
0,2% na neovascularização corneal induzida pelo implan-
te de membrana amniótica xenógena em microbolsa no
estroma da córnea de ratos.] Este estudo teve como ob-
jetivo a avaliação dos efeitos tópicos da Ciclosporina a 0,2%
(CsA) sobre a neovascularização corneana de ratos após
implante cirúrgico de membrana amniótica eqüina em
microbolsa do estroma corneana. O implante da membra-
na foi feito bilateralmente em 90 ratos. O tratamento com
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The objective of the study was to evaluate the topical effects of 0.2% Cyclosporine A
(CsA) on corneal neovascularization of rats following surgical implantation of equine amniotic
membrane into a corneal stroma micropocket. The implantation of xenologous amniotic
membrane was performed bilaterally in 90 rats. In the same day of the surgery each right
eye started receiving topical CsA twice a day. The left eye received no medication and
served as a control. The evaluation of corneal neovascularization was performed by
computerized image analysis and histopathological evaluation at 1, 3, 7, 15, 30 and 60
days postoperatively. For the image analysis 10 animals were used per time period, and
for the histopathological examination, five animals were used per time period. Image analysis
found that corneal neovascularization began on the 3rd postoperative day, reached its
peak on the 7th day, and then progressively and rapidly decreased. Statistic analysis
indicated that neovascularization of the CsA treated eye on the 7th day was significantly
higher than that observed in untreated eyes. On the 30th day, however, this pattern was
reversed with the neovascularization observed in the CsA treated eyes declining to the low
levels observed on the 3rd day. The degree of neovascularization in the untreated eyes on
the 30th day declined to the baseline levels found on day 3 at the 60th day. Histopathological
analysis indicated that deposition of collagen in the implanted tissue was completed by the
15th day. Therefore, we concluded that (1) equine amniotic membrane in rat corneal stroma
produced an intense neovascularization until the 15th day postoperatively and then
regressed, (2) deposition of collagen of the implanted tissue was completed on the 15th
day postoperatively, and (3) use of CsA was associated with increase in the corneal
neovascularization initially, followed by a quick and intense regression.
INDEX TERMS: Amniotic membrane, cyclosporine, cornea, veterinary, ophthalmology.
Pesq. Vet. Bras. 28(8):379-386, agosto 2008
Juliana F. Milani et al.380
CsA iniciou-se no mesmo dia da cirurgia, nos olhos direitos
dos animais, duas vezes ao dia. Os olhos esquerdos não
receberam nenhum tratamento e serviram de controle. A
avaliação da neovascularização corneana foi feita por análi-
se de imagem computadorizada e por exame histopatológi-
co aos dias 1, 3, 7, 15, 30 e 60 de pós-cirúrgico. Para a
análise de imagem foram utilizados 10 animais por período,
e para o exame histopatológico, 5 por período. A análise de
imagem demonstrou que a neovascularização iniciou-se no
3° dia pós-cirúrgico, alcançou seu pico no 7° dia e então
regrediu rápida e progressivamente até o 60° dia. A análise
estatística indicou que a neovascularização no 7o dia nos
olhos tratados com CsA foi significantemente mais acentua-
da do que aquela observada nos olhos não tratados. Entre-
tanto, no 30o dia este fato se reverteu, e a neovasculariza-
ção observada nos olhos tratados com CsA diminuíra a ní-
veis baixos comparáveis àquela do 3o dia. Já nos olhos não
tratados, o grau de neovascularização somente pôde ser
comparado àquele nível básico encontrado no 3o dia aos 60
dias de pós-operatório. A análise histopatológica demons-
trou que a deposição de colágeno no tecido implantado se
completou no 15o dia. Desta maneira, foi possível concluir
que (1) a membrana amniótica em estroma corneano de
ratos produz intensa neovascularização até o 15o dia de pós-
operatório com posterior regressão, (2) a deposição de
colágeno do tecido implantado foi completa ao 15o dia de
pós-operatório, e que (3) o uso de CsA esteve associado
com aumento inicial da neovascularização corneana, segui-
do de rápida e intensa regressão.
TERMOS DE INDEXAÇÃO: Membrana amniótica, ciclosporina,
córnea, veterinária, oftalmologia.
INTRODUCTION
Biologic membranes grafts such as amnion, pericardium,
renal capsule, and conjunctiva are being used for the repair
of corneal diseases such as deep ulcerative keratitis,
descementocele, staphyloma, iris prolapse, or after excision
of cornea, sclera or limbal tumors. The problem with such
membranes is that they induce varying amounts of neo-
vacularization and/or opacity of the cornea to result in de-
creased vision of the patient (Hakanson & Merideth 1986,
Barros et al. 1995, Andrade et al. 1999, Godoy et al. 2002).
The angiogenic producing capacity of biologic mem-
branes can vary. A study comparing xenologous amniotic
membrane with xenologous pericardium using micropocket
implants in rat corneal stroma demostrated that the
pericardium induced more corneal neovasculari-zation
than amniotic membrane (Safatle et al. 2002). Another
study showed that angiogenesis was effectively retarded
by cyclosporine in rat models of corneal angiogenesis
induced by xenotransplantation and/or by chemical
cauterization (Benelli et al. 1997). Many drugs have been
used to suppress angiogenesis such as cytokine inhibitors
interleukin-1 receptor antagonist (Coxon et al. 2002), FGF
inhibitors as rapamycin (Kwon & Kim 2006),  FGF-2
inhibitors as hypericin (Lavie et al. 2005), doxycycline and
triancinolone (Riazi-Esfahani et al. 2006), anti-VGEF
antibodies as ranibizumab (Lucentis®) (Heier et al. 2006),
pegaptanib (Macugen®) (Macugen Diabetic Retinopathy
Group 2006), bevacizumab (Avastin®) (Manzano et al.
2006, Barros & Belfort Jr 2007, Hosseini & Nejabat 2007)
or VEGF trap drugs (Liu et al. 2006).
This study evaluated the topical effect of 0.2%
cyclosporine A by histopathological and computerized
image analysis on corneal neovascularization of rats with
implantation of equine amniotic membrane in a
micropocket of corneal stroma.
MATERIALS AND METHODS
Animals. Ninety female, adult, healthy Wistar rats without
any corneal injury with an average weight of 200g were used.
The animals were kept in appropriate boxes and wood shavings,
and fed with ad libitum water and animal feed.
Anesthesia. Animals were anaesthetized by intraperitoneal
injection of 0.1ml/100g of ketamine chloral hydrate (50mg/ml)
and xylazine chloral hydrate, associated at the rate of 2:1.
Implant of the amniotic membrane. Equine amniotic
membrane, stored in 98% glycerin was used. The implant was
hydrated with a solution of sodium chloride 0.9% for 15 minutes
prior to implantation. With the animal anaesthetized and in lateral
recumbency,  an operating microscope with a number 11 needle
without a bevel was used to perform a longitudinal incision about
0.3mm from the limbus followed by dissection of the corneal
stroma towards the center of the cornea. A microcavity or pocket
was formed between the collagen layers up to ¾ of the cornea
radius. Fragments (1mm X 1mm) of amniotic membrane were
then inserted inside each micropocket in both eyes. This pocket-
surgery has been previously proved not to cause any significant
neovascularization alone (Safatle et al. 2002).
Treatment with 0.2% Cyclosporine A (CsA). Right after
the implantation of the amniotic membrane in the rat corneas,
the treatment with 0.2% Cyclosporine A (ointment presentation
- Optimmune®/Shering-Plough) was initiated twice a day in right
eyes only (the left eyes serving as controls).
Filling of the vascular bundle with Nankeen Ink. Animals
were deeply anaesthetized on the 1st, 3rd, 7th, 15th, 30th and
60th day postoperatively (10 animals per period). The animals
were catheterized and given intravenous (femoral vein) heparin
(500 UI). Five minutes later, the thoracic region skin was incised
and the thorax was opened through a mediastinal incision.
Animals were then euthanized by exsanguination through an
incision in the left ventricle, and a cannula was put in the
brachiocephalic trunk to slowly infuse 10ml of Nankeen Ink
(Faber-Castell®) in order to fill the vasculature. The eyes were
enucleated and fixed in Formaldehyde 10%.
Dehydration and diaphanous rendering (Spalthölz
Method).  After 48 hours, the eyes were washed for one hour in
running water, dehydrated in crescent alcoholic solutions (50oGL,
60oGL, 70oGL, 80oGL, 95oGL and 100%, 24 hours in each
solution), rendered diaphanous in two passages of 24 hours
each of benzol, and preserved in a solution of methyl salicylate
and benzyl benzoate (mixed at the rate of 5:3). The corneas
were then removed from the eyes, divided into two equal parts,
and put between two microscope glass slides fixed by staples
(paper staple of grampomol type), in such a way 48 hours later
the corneas were totally widened and could be fixed between a
microscope glass slide and a microscope covers lip with resinoid.
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Quantifying of corneal neovascularization by computerized
image analysis. The neovascularization density in a defined area
was used to quantify the neovascularization of the corneas after
diaphanous rendering. The area utilized was a rectangle of defined
area (x) in the most vascularized region between the limbus and
the implant, as close as possible to the limbus. To choose the most
vascularized area a computer system (Bio Scan Optimas®)
indicated the degrees of vascularization with different colors. The
software also gave the area of vascularization inside the rectangle
(y), which was different for each sample. The neovascularization
density for each sample was obtained by dividing (y) by (x). The
rectangular area (x) was kept constant for all samples.
Statistic analysis. Statistic analysis was performed at a 5%
level of significance by means of four comparisons of the
neovascularization: analysis of the averages and their standard
deviations; analysis of variances with repeated measures;
Bonferroni’s and Tukey-Kramer’s multiple comparisons between
the eyes; and Bonferroni’s and Tukey-Kramer’s multiple
comparisons between the periods.
Histopathological analysis. We analyzed corneas from the
eyes of 1st, 3rd, 7th, 15th, 30th and 60th days postoperatively (five
per period). For this, the eyes were preserved in formaldehyde
10% for 24 hours. Afterwards the corneas were removed
(preserving the cornea-sclera region) and sectioned into four
parts. The parts with the implant were dehydrated in alcoholic
solutions of crescent concentrations, included in paraffin and
sectioned into a microtome (5mm of thickness). Thereafter, the
fragments were stained with haematoxylin-eosin (HE) and
analyzed under a light microscope.
RESULTS
Computerized image analysis
Computer image analysis indicated that there was
obvious neovascularization beginning the 3rd day
postoperatively, reaching its peak on the 7th day
postoperatively, and then decreasing until the 15th day
postoperatively (Fig.1, 2). A progressive decrease until
Fig.1. Rat cornea after intravenous injection of Nankeen Ink 15
days after the implantation of amniotic membrane, without
treatment. Observe the corneal neovascularization involving
the amniotic membrane implant ().
Fig.3. Rat cornea after intravenous injection of Nankeen Ink 60
days after the implantation of amniotic membrane, without
treatment. Note that the neovascularization is almost absent.
(= amniotic membrane implant)
Fig.2. Rat cornea after intravenous injection of Nankeen Ink 15
days after the implantion of amniotic membrane and
treatment with CsA. Observe smaller corneal neovasculari-
zation involving the amniotic membrane implant (), com-
paring with Figure 1.
Fig.4. Rat cornea after intravenous injection of Nankeen Ink 60
days after the implantation of amniotic membrane, with topical
treatment with CSA. Note that the neovascularization is
almost absent. (= amniotic membrane implant)
3
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the 60th day postoperatively was later observed (Fig.3, 4).
Such analysis did not indicate that there was an individual
difference in neovascularization between treated and
untreated eyes.
Statistical analysis
Analysis of averages and their standard deviations
indicated there was more obvious neovascularization the
3rd day postoperatively and reaching its peak in treated
and no treated groups on the 7th day postoperatively. The
neovascularization decreased rapidly until the 15th day
postoperatively, and then more regressed until the 60th
day postoperatively. Analysis of variances with repeated
measures indicated that there was a significant difference
in the interaction term (p=0.0067), i.e., neovascularization
densities vary in a different way between treated and
untreated eyes in each period.
Bonferroni’s and Tukey-Kramer’s multiple comparisons
between eyes found that the variation indicated in analysis
of variance occurred on the 7th day, and that treated eyes
showed more neovascularization than untreated eyes.
Bonferroni’s and Tukey-Kramer’s multiple comparisons
between periods were performed for both treated and
untreated eyes, and indicated:
Treated eye. There was neovascularization equivalence
among days 1, 3, 30 and 60, which differed from days 7
and 15, which are equivalent between themselves.
Untreated eye. There was neovascularization
equivalence among days 1, 3 and 60, but not between
day 30, which was equivalent to day 15. There was also
equivalence between day 7 and 15.
Therefore, statistical analysis found that the peak of
neovascularization occurred on the 7th day postoperatively,
and that eyes treated with CsA had a larger peak than
untreated eyes. However, on the 30th day postoperatively,
such a difference was inverted, and untreated eyes showed
more neovascularization than treated eyes (Fig.5).
Histopathologic analysis
Histopathologic analysis indicated that on the 1st day
postoperatively there was intense inflammatory reaction
at the limbus both in treated and in untreated eyes. On the
3rd day, there was a small amount of neovascularization
in the implant region. On the 7th day, neovascularization
became more obvious, and deposition of collagen in the
implant begins. On the 15th day, there was total deposition
of collagen in the implant area (Fig.6, 7, 8). On the 30th
day, neovascularization displayed clear signs of regression
and amniotic membrane becomes confounding with
stroma, especially in eyes treated with CsA. On the 60th
Fig.5. Averages and their respective standard errors of  neo-
vascularization densities obtained from corneas of eyes
treated with CsA (right eye) and of untreated eyes (left eye)
in the periods of 1, 3, 7, 15, 30 and 60 days postoperatively.
Through the image, it is observed a difference between the
vascularization densities of the left and the right eye on day
7. After that, we observed that treated eyes had a quicker
and more intense regression of neovascularization than
untreated eyes.
Fig.7. Rat cornea 15 days after amniotic membrane implantation
and topical treatment with CsA, illustrating superficial
epithelial regeneration in the implant area (1). In the
underlying tissue an obvious cell proliferation intermixed with
extracellular matrix can be observed (2). HE, scale bar =
10μm.
Fig.6. Rat cornea 15 days after amniotic membrane implant,
without treatment, indicating epithelial regeneration (1), and
fibroblastic proliferation in the implant area, with clear signs
of deposition of collagen (2). HE, scale bar = 10μm.
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day, the cornea is almost normal without neovasculari-
zation or signs of eyes implant (Fig.9).
DISCUSSION
Amniotic membrane has been widely used in oph-
thalmology for corneal repair, especially in cases with loss
of the stroma tissue such as deep ulcerative keratitis,
descemetocele, loss of cornea-sclera tissue after excision
of neoplasias, symblepharon, eye burns, and pterygia
among others (De Rotth 1940, Lee & Tseng 1997,
Shimazaki et al. 1997, Cheng et al. 2000, Chikamoto et al.
2001, Hanada et al. 2001, Solomon et al. 2001, 2002,
Espana et al. 2002).
In veterinary medicine its utility has been growing. For
instance, it has been already used to repair full-thickness
defects of the cornea of dogs (Barros et al. 1998),
generalized keratomalacia, ankyloblepharon, and after
fibrous histiocytoma removal in two dogs and a cat (Bar-
ros et al. 2005), to reconstruct corneal surface after
excision of corneolimbal squamous cell carcinomas in nine
horses (Olliver et al. 2006), and to repair corneal ulceration
and keratomalacia in three horses (Lassaline et al. 2005).
It has also been used in human patients with deficient
production of limbal stem-cells, not solely for eye
reconstruction, but also for the ex vivo culture of such cells
(Tsai et al. 2000, Anderson et al. 2001, Meller et al. 2002,
Pan et al. 2002, Ti et al. 2002).
The amniotic membrane is a thin tissue, semi-
transparent with a thick and continuous basal membrane,
and an avascular stromal matrix (Van Herendael et al.
1978, Modesti et al. 1984). It has a great immunological
advantage, since its cells do not express leukocyte
antigens of class I, and has some immunoregulatory
factors rendering it less susceptible to transplant rejection
(Adinolfi et al. 1982). The main advantages of its use in
the reconstruction of the eye surface include: viability of
the amnion, convenience and facility of its use, and facility
of forming a new epithelium with decreased inflammation,
vascularization and eye secretion (Tseng 2001).
However, its use leads to corneal neovascularization
which has an important role in reabsorbing the implanted
amniotic membrane and in deposition of stromal collagen,
besides being responsible for injured cornea’s cicatrization
(Rehany & Waisman 1994, Gris et al. 2002). Notwith-
standing, such neovascularization also leads to undesired
effects, such as loss of corneal transparency with
decreased visual acuity and intense inflammatory
response, and with loss of the immunological advantage
and possible rejection of the transplant tissue (Rehany &
Waisman 1994).
Cyclosporine A is a cyclic polypeptide from fungus
Tolypocladium inflatum Gans, and presents the ability to
inhibit the activation and proliferation of T-helper
lymphocytes by blocking the release of lymphokines
(Diasio & Lobuglio 1996). It has been systemically used
since 1979 in preventing transplant and for immunological
diseases (Calne et al. 1979). In ophthalmology, it is used
specially for decreasing cases of rejection of corneal
implant and transplant (Calatayud et al. 2001). Since its
systemic use has a high cost and results in several
collateral effects, and its topical use leads to concentration
levels in corneal epithelium higher than when it is used
systemically, ophthalmologists began to use eye drops or
ointments for the application of cyclosporine (Ponn et al.
2001, Theng et al. 2002).
Our study indicated that amniotic membrane implant
led to corneal neovascularization which reached its peak
on the 7th day postoperatively, with a slight decrease until
the 15th day and then total regression at 60 days. On the
15th day at the implant site, the corneal epithelium
regenerated, and deposition of collagen in the stromal
implant site was total. Topical application of CsA twice a
day led to an increase in neovascularization in the
Fig.9. Rat cornea 60 days after amniotic membrane implantation
after treatment with CsA, finding regenerated epithelium (1)
and underlying area of implant with deposition of collagen
(2). HE, scale bar = 10μm.
Fig.8. Rat cornea 60 days after amniotic membrane implantation
without treatment, illustrating pluristratified epithelium (1) and
an underlying area with dense connective tissue, in
substitution of the implant tissue (2). HE, scale bar = 10μm.
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beginning of the treatment, with a quicker and more intense
regression of neovascularization as of the 15th day when
comparing treated to untreated eyes.
While one study detected Beta Transforming Growth
Factor (TGF-) in vascularized corneas, another study
demonstrated that TGF-b is related to the tridimensional
structure of capillary structures “like” in vitro. (Cursiefen et
al. 2000, Darland & D`Amore 2001). Since Cyclosporine
stimulates the expression of TGF-b in humans, in vivo and
in vitro, this may be one of the mechanisms that led to an
increase in neovascularization at the beginning of the
experiment (7 days postoperatively) (Suthanthiran & Strom
1994, Khanna et al. 1997, Goodman et al. 2001, Stabellini
et al. 2002).
One study evidenced that after a corneal injury,
neovascularization process begins with a non-proliferative
stage in the first 48 hours, followed by a proliferative stage
with a high rate of vascular growth and, thereafter, with a
regression stage with decrease in density of the new
vessels (Edelman et al. 1999). It is hypothesized that in
the first two stages there is an increase in expression of
the Vascular Endothelium Growth Factor (VEGF), whilst
in regression stage there is a decrease of VEGF, thus
suggesting that the increase in expression of VEGF is
important for inducing and maintaining the neovas-
cularization in cornea, and that its decrease leads to a
regression of neovascularization (Edelman et al. 1999).
Another study demonstrated that VEGF needs activation
of Nuclear Factor of Activated T-Cells (NFAT) for inducing
the genetic expression of Cyclo-Oxygenase-2 (COX-2) in
endothelium cells (Hernandez et al. 2001). Since CsA
inhibits NFAT, the angiogenesis stimulated and maintained
by VEGF also is inhibited by CsA (Chreiber & Crabtree
1992, Erlanger 1992, Mascarell & Truffa 2002). Therefore,
we demonstrated the possible mechanism through which
CsA stimulated regression of neovases in our study.
CsA also inhibits Interleucin-2 (IL-2) and Interferon-
Gamma (INF-g) that are associated to activation of
macrophages (Hingorani et al. 1999). Macrophages are
directly related to the angiogenesis, liberating proteolytic
enzymes responsible for the discontinuance of vascular
stability (Auerbach & Auerbach 1994). Hence, the use of
CsA may inhibite the activation of macrophages and
decrease the neovascularization by this mechanism.
Therefore, the use of Cyclosporine may be indicated in
the postoperative period for implant/transplant of amniotic
membranes in cornea in a way to decrease neovasculari-
zation led by its initial stage.
Our study concluded that equine amniotic membrane in
rat corneal stroma led to an intense neovascularization until
the 15th postoperative day followed by later regression;
collagen deposition of the implanted tissue was entirely
achieved on the 15th postoperative day, and use of CsA
was linked with increase in the corneal neovascularization
at first, followed by a rapid and intense regression.
However, many other factors are involved in corneal
neovascularization, as well as in cyclosporine’s mecha-
nism of action; so several studies in this area will still be
necessary to elucidate the way Cyclosporine acts on
transplant angiogenesis.
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